#USA #Securities Fraud #Berger Montague #Gaithersburg #Altimmune

Investor Alert: Class Action Lawsuit Against Altimmune Inc.

On September 22, 2025, the national law firm Berger Montague announced a significant class action lawsuit against Altimmune Inc. (NASDAQ: ALT), representing investors who acquired shares during the period from August 10, 2023, to June 25, 2025. This lawsuit highlights serious allegations of securities fraud that potential claimants need to address by October 6, 2025, to participate as lead plaintiff representatives.

Background on Altimmune

Altimmune Inc., based in Gaithersburg, Maryland, is a clinical-stage biopharmaceutical company engaged in developing innovative treatments, particularly for obesity and liver diseases such as MASH (metabolic dysfunction-associated steatohepatitis). The company aims to deliver effective solutions in an industry known for its challenging clinical outcomes.

The Allegations

The crux of the case lays in events following Altimmune's public announcement on June 26, 2025, which detailed the outcomes of its IMPACT Phase 2b trial assessing the efficacy of Pemvidutide for treating MASH. While there had been numerous optimistic statements from company executives regarding trial expectations, the results contradicted earlier assessments, revealing statistical insignificance in the primary endpoint concerning fibrosis reduction due to an unexpected high placebo response. This information shocked investors, leading to a drastic decline in Altimmune's stock price by 53.2% in just one day, plummeting from $7.71 to $3.61 per share.

Call to Action for Investors

Investors who were affected by this sudden downturn and who acquired shares during the specified time frame are urged to investigate their eligibility for this class action. Berger Montague has not only committed to representing these investors but also emphasizes the importance of understanding their rights, with contact points listed for those seeking further details.

If you purchased or acquired Altimmune securities during the class period, you are encouraged to reach out to Berger Montague for clarification on your rights and options available to you regarding this lawsuit. Interested parties can contact Andrew Abramowitz at (215) 875-3015 or Caitlin Adorni at (267) 764-4865 for assistance.

About Berger Montague

Founded in 1970, Berger Montague has a long-standing reputation as a pioneer in securities class action litigation. With offices strategically located in Philadelphia, Minneapolis, and several other cities, they have been at the forefront of advocating for both individual and institutional investors across the United States. The firm prides itself on its comprehensive understanding of financial complexities and a robust strategy for representing the rights of its clients.

In summary, the Altimmune class action presents an opportunity for aggrieved investors to seek justice for their losses amid circumstances that appear to involve significant misrepresentations by the company. The deadline to act is fast approaching, and investors are encouraged to assess their situation promptly to safeguard their interests in this unfolding legal matter.